US IPO Pipeline SEC S-1 Filings — April 10, 2026

10-04-2026

Aeon Acquisition I Corp. (AESP), a blank check company, filed an S-1 registration statement on April 10, 2026, for an IPO of 25,000,000 units, each comprising one Class A ordinary share, one warrant, and one right, with an additional 300,000 private units. Post-offering (assuming no underwriter over-allotment), 25,300,000 units, 36,014,286 Class A ordinary shares (including 25,000,000 public, 10,714,286 founder, and 300,000 private), 25,300,000 warrants, and 25,300,000 rights will be outstanding. Warrants are exercisable at $11.50 per share 30 days after an initial business combination and redeemable at $0.01 if the Class A share price meets or exceeds $18.00 for specified periods.

• ·Founder shares (Class B) consist of 12,321,429 pre-offering, convertible to Class A on a one-for-one basis upon business combination.
• ·Up to 1,607,143 founder shares to be surrendered for no consideration based on underwriter over-allotment exercise.
• ·No fractional warrants or rights issued; whole warrants trade and rights exercisable in multiples of five.
• ·Post-effective amendment or new registration for warrant shares to be filed within 15 business days after business combination closing.

10-04-2026

Seaport Therapeutics, Inc. filed an S-1 registration statement on April 10, 2026, for an initial public offering of voting common stock on Nasdaq under the symbol 'SPTX', with net proceeds estimated at approximately $XM (midpoint assumed IPO price) to fund development of GlyphAlloTM (SPT-300), GlyphAgoTM (SPT-320), and Glyph2BLSDTM (SPT-348), plus other R&D and working capital. For the year ended December 31, 2025, the company reported a net loss of $74.9M, up 60% YoY from $46.9M in 2024, driven by R&D expenses surging 164% to $66.3M, though G&A expenses declined 23% to $21.0M; cash, cash equivalents, and investments stood at $46.0M. Post-offering and preferred stock conversion, approximately 122,072,236 shares of common stock will be outstanding.

• ·Pro forma net loss per share for 2025: $(0.62) on 121,377,047 pro forma shares.
• ·27,633,144 shares of common stock issuable upon exercise of options as of Dec 31, 2025 (weighted-average exercise price $1.52/share).
• ·IPO Grants to executive officer and director to maintain ~12.5% ownership on fully diluted basis post-IPO.
• ·Underwriters' 30-day option to purchase up to additional shares at public offering price.
• ·1-for-X reverse stock split to be effective prior to offering completion.

10-04-2026

Longeveron Inc. filed an S-1 registration statement on April 10, 2026, to register for resale up to 30,865,385 shares of Class A common stock by selling stockholders, stemming from a private placement with initial closing gross proceeds of approximately $15.9 million. However, the company faces significant challenges including Nasdaq minimum bid price non-compliance (deadline September 21, 2026), temporary audit committee composition issues following a director resignation, and a going concern opinion due to working capital deficiency and losses. Potential dilution is notable with post-offering Class A shares potentially reaching 52,649,134 assuming conversions and exercises.

• ·Nasdaq minimum bid price non-compliance notice received September 22, 2025; initial 180-day period until March 23, 2026; second 180-day extension until September 21, 2026.
• ·Audit Committee temporarily non-compliant after March 3, 2026 resignation of Richard Kender; Dr. Roger Hajjar appointed March 4, 2026; plans to appoint independent audit committee financial expert within 180 days or at next annual meeting.
• ·PA Warrants exercisable immediately at $0.65 per share for 5 years.
• ·Excludes from outstanding shares: 22,326,547 shares from outstanding warrants, 1,000,265 RSUs, 837,887 stock options (avg $2.61), and 50,000 third-party options ($2.15).

10-04-2026

Alpex Acquisition Corp, a Cayman Islands-incorporated blank check company, filed an S-1 registration statement on April 10, 2026, for an initial public offering of 10,000,000 units at $10.00 each, aiming to raise $100,000,000 to pursue a business combination with no industry or geographic restrictions. Each unit includes one Class A ordinary share and one right (with five rights convertible to one Class A share post-combination), with underwriters granted a 45-day over-allotment option for 1,500,000 additional units. Insiders hold 2,875,000 Class B shares (approximately 20% ownership post-IPO) and sponsor committed to 180,000 private units for $1,800,000; the company has 18 months (extendable to 24) to complete a business combination or liquidate.

• ·Business combination must be completed within 18 months from IPO closing (extendable to 24 months if definitive agreement signed within 18 months).
• ·Promissory note issued March 3, 2026, payable without interest by December 31, 2027, or IPO closing.
• ·Sponsor total investment: $1,821,000 for 2,280,000 shares and 180,000 rights (converting to 36,000 shares post-combination).

10-04-2026

Hemab ApS, a clinical-stage biotech, filed an S-1 registration statement for its IPO on April 10, 2026, showing total assets doubling to $194,783 thousand as of December 31, 2025 from $96,278 thousand in 2024, fueled by $156,421 thousand net proceeds from Series C convertible preference shares issuance, which increased cash and cash equivalents to $87,974 thousand and marketable securities to $97,511 thousand. However, the company reported a widened net loss of $63,913 thousand in 2025 from $48,707 thousand in 2024, driven by research and development expenses rising 44% YoY to $59,632 thousand, with operating cash burn intensifying to $61,475 thousand. Stockholders' deficit deepened to $(176,635) thousand from $(115,273) thousand amid ongoing clinical development.

• ·Lead asset sutacimig (HMB-001) in Phase 1/2 for Glanzmann thrombasthenia and Phase 2 for Factor VII deficiency.
• ·Second asset HMB-002 in Phase 1/2 for Von Willebrand Disease.
• ·Auditor: EY since 2021; report dated February 27, 2026 (except Note 16: April 10, 2026).
• ·Liquidation preferences: Series Seed $2,939k, Series A $54,528k, Series B $135,248k, Series C $156,898k as of Dec 31, 2025.

10-04-2026

Irenic Acquisition Corp., a Cayman Islands-incorporated blank check company, filed an S-1 registration statement on April 10, 2026, for an initial public offering of 22,000,000 units at $10.00 each, raising $220,000,000 in gross proceeds, with each unit consisting of one Class A ordinary share and one-third of one redeemable warrant exercisable at $11.50 per share after the initial business combination. Underwriters have a 45-day option to purchase up to an additional 3,300,000 units to cover over-allotments. The SPAC has not selected any specific business combination target and has no prior operations.

• ·Warrants become exercisable 30 days after completion of initial business combination and expire five years thereafter or earlier upon redemption or liquidation.
• ·Company has engaged in no substantive discussions with any business combination targets.
• ·Sponsor: Irenic Sponsor LLC; principal office: 767 Fifth Avenue, 15th Floor, New York, New York 10153.

10-04-2026

C2 Capital Group, Inc., a Nevada-incorporated emerging growth company, filed an S-1 registration statement on April 10, 2026, for a firm commitment initial public offering of 3,750,000 shares of common stock at an anticipated price range of $4.00 to $5.00 per share (midpoint $4.50), with application to list on NYSE American under symbol 'CCLV'. The filing also registers 666,880 shares for resale by selling stockholders via a separate prospectus and includes a 45-day underwriter over-allotment option for up to 562,500 additional shares. Underwriting terms feature warrants for 8% of shares sold and a 1.0% non-accountable expense allowance; no financial performance data is detailed in the provided content.

• ·Filing date: April 10, 2026
• ·Principal executive offices: 7700 Congress Avenue, Suite 3105, Boca Raton, FL 33487
• ·State of incorporation: Nevada
• ·SIC Code: 2741
• ·I.R.S. Employer Identification Number: 20-5379243
• ·Emerging growth company and smaller reporting company status confirmed

10-04-2026

Encore Inc. filed an S-1 registration statement with the SEC on April 10, 2026, for its initial public offering, including detailed accounting policies for revenue recognition under ASC 606, venue incentives, and other financial statement notes. Advertising costs declined from $8,912 in 2023 to $6,743 in 2025, while the allowance for credit losses remained relatively stable, decreasing slightly from $6,761 at December 31, 2024, to $6,722 at December 31, 2025. Restricted cash dropped to $0 at December 31, 2025, from $4,305 at December 31, 2024, with no material impairments of venue incentives reported for 2023-2025.

• ·Provision for credit losses: $3,269 (2024), $2,892 (2025)
• ·Charge-offs: $(5,900) (2024), $(3,090) (2025)
• ·No material impairments of venue incentives during years ended December 31, 2025, 2024, or 2023
• ·Venue contracts typically range from three to six years
• ·Annual goodwill impairment test as of October 1st

10-04-2026

Pelican Holdco, Inc. filed an S-1 registration statement on April 10, 2026, including a resale prospectus for certain selling stockholders to potentially resell shares of common stock. The filing follows the completion of a business combination, after which the company states it is no longer a shell company. Various equity transactions and subsequent events involving entities like Greenland Exploration Limited and Pelican Acquisition Corporation are referenced from 2025 through early 2026.

• ·Business combination completion referenced around September 2025.
• ·Pelican Acquisition Corporation IPO and private placement activities in May 2025.
• ·Multiple subsequent events for Greenland Exploration Limited from October 2025 to March 2026.

10-04-2026

Propanc Biopharma, Inc. (PPCB) filed an S-1 Registration Statement on April 10, 2026, likely in preparation for an IPO or securities offering. The filing references multiple periods including FY2025 (up to 2025-12-31) and prior periods, with disclosures on Series A, B, and C Preferred Stock, warrants, related party loans, debt exchanges, and transactions with entities like Crown Bridge Partners LLC. No specific financial performance metrics are detailed in the provided excerpt, highlighting ongoing capital raising activities amid complex equity and debt structures.

• ·Balance sheet tags for periods including 2025-12-31, 2025-06-30, 2024-12-31, and 2024-06-30 covering Preferred Stock (Series A, B, C), Common Stock, Additional Paid-in Capital, Retained Earnings.
• ·Transactions include debt exchanges (e.g., 2025-01-23 with Former Director), loan agreements (multiple dates in 2024-2025), securities purchase agreements, and maturity extensions (e.g., 2025-05-07).
• ·Subsequent events noted post-2025-06-30, such as common stock issuance on 2025-08-18 and Series C Preferred Stock on 2025-11-04.

10-04-2026

HawkEye 360, Inc. filed an S-1 registration statement on April 10, 2026, for its initial public offering of common stock, estimated at between $X and $Y per share (blanks in preliminary prospectus), with plans to list on the NYSE under 'HAWK'. The company, founded in 2015, provides signals intelligence (SIGINT) and RF data solutions to the U.S. Government and allies, recently acquiring Innovative Signal Analysis, Inc. (ISA) in December 2025 to enhance signal processing capabilities. As an emerging growth company, it will elect public benefit corporation status post-IPO, balancing stockholder value with national security interests.

• ·Founded in 2015 by military veterans, engineers, and national security technologists.
• ·Standard Industrial Classification Code: 7374; I.R.S. Employer Identification No.: 47-5078666.
• ·Principal executive offices: 450 Springpark Place, Suite 500, Herndon, Virginia 20170.
• ·Underwriters granted 30-day option to purchase additional shares.
• ·Emerging growth company electing not to use extended transition period for new accounting standards.

10-04-2026

Suja Life, Inc. filed an S-1 registration statement with the SEC on April 10, 2026, for its initial public offering of Class A common stock. As an emerging growth company under the JOBS Act, it expects to qualify for exemptions including delayed auditor attestation under SOX Section 404 until the later of the year after its first annual report or up to 2031, unless annual gross revenues exceed $1.235 billion or it issues over $1.0 billion in non-convertible debt in a three-year period. The filing discloses significant risks such as potential material weaknesses in internal controls, high costs and management distraction from public company compliance, reduced disclosure making stock less attractive, and the need for additional dilutive financing.

• ·Emerging growth company status eligible for up to five years post-IPO, with fifth anniversary in 2031.
• ·Electing extended transition period under JOBS Act for new/revised accounting standards, potentially making financials less comparable to other public companies.
• ·Public company compliance may increase legal, accounting, and insurance costs, divert management attention, and strain resources.

10-04-2026

Bravalo Corporation, a Wyoming-incorporated development-stage company focused on AI-powered headline generation services since October 27, 2025, is registering 5,000,000 shares of common stock at $0.025 per share for a best-efforts IPO aiming to raise up to $125,000, with no minimum required. For the fiscal year ended December 31, 2025, the company reported no revenue, a net loss of $14,478, and total assets of $22,176, underscoring its foundational stage and funding needs of at least $25,000 for the next 12 months. The company is 100% owned by director Valencia Pena Alexander, who invested $9,000 in equity for 1,800,000 shares and provided a $229 loan from a $200,000 commitment.

• ·Incorporated on October 27, 2025 in Wyoming
• ·Offering price of $0.025 per share arbitrarily determined, unrelated to assets, book value, or earnings
• ·Best-efforts offering to terminate after 365 days, full sale, or board decision
• ·Plans to seek OTC Markets quotation post-effective date, no current market maker
• ·Emerging growth company with reduced reporting requirements